

State of the Nation Report 2026

Summary of results for people diagnosed with oesophageal or gastric (OG) cancer in England and Wales between 1 January 2023 and 31 December 2024



NOGCA

National Oesophago-Gastric Cancer Audit

20,441

people diagnosed with OG cancer in England and Wales between 1 January 2023 and 31 December 2024

E England: 19,161

W Wales: 1,280

Route of diagnosis



E 21%
W 13%

% people diagnosed after emergency admission


Stage at diagnosis

4


E 45%
W 42%

% people diagnosed with stage 4 disease


Patient profile at diagnosis




Median time from diagnostic endoscopy to first disease-targeted treatment for OG cancer^a (PI 1)



% people with a diagnosis of OG cancer who are seen by a Clinical Nurse Specialist^b (PI 2)




% people diagnosed with stage 1-3 OG cancer (PS 0-1) who initiated potentially curative treatment (PI 3)



90-day survival rate after curative surgery^c (PI 4)



% people with length of stay >15 days following curative surgery^c (PI 5)




% people readmitted to hospital within 30 days of discharge following curative surgery^c (PI 6)




% people starting palliative systemic anti-cancer therapy (SACT) completing at least four cycles of treatment (PI 7)



% people diagnosed with stage 4 disease dying within 90 days of starting SACT (PI 8)



One-year survival



Fewer than 10% of people diagnosed with OG cancer at stage 4 survived to three years after diagnosis

National performance across OG cancer indicators in England showed little change between 2021 and 2024. (Change over time is not presented for Wales due to changes in data collection approaches in recent years, making comparisons inappropriate.)

Key
PI: Performance Indicator
PS: Performance Status
OG: Oesophago-Gastric
Oes SCC: Oesophageal squamous cell carcinoma
Oes ACA: Oesophageal adenocarcinoma
Gast. cancer: Gastric (stomach) cancer***

a. Measured from date of first endoscopy within 30 days of date of diagnosis and date of first disease-targeted treatment of EMR/ESD, surgery, radiotherapy, or SACT.
b. Data available for 73% of patients in England and 90% of patients in Wales.
c. 3 years' of data (1 Jan 2022 - 31 Dec 2024) used for surgical outcomes to produce robust statistics; results are the % for people undergoing surgery.

* Variation is the IQR or range across providers;
** Variation data not available for Wales;
*** Data for surgical centres in Wales were not available for this analysis at the time of reporting due to limitations in reliably allocating people to surgical centres - thus variation not reported.